Возможности влияния современной фармакотерапии на исход заболевания при хронической обструктивной болезни легких

1. Wouters E.F. Economic analysis of the Confronting COPD survey: an overview of results. Respir. Med 2003; 97 (suppl. C): S3–S14.

2. Calverley P.M., Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362: 1053–1061.

3. Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.

4. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–686.

5. Chapman K.R., Mannino D.M., Soriano J.B. et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 188–207.

6. Rabe K.F., Hurd S.A. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 532–555.

7. Eriksen N., Hansen E.F., Munch E.P. et al. Chronic obstructive pulmonary disease. Admission, course and prognosis. Ugeskr. Laeger. 2003; 165 (37):3499–3502.

8. Connors A.F., Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154: 959–967.

9. O'Donnell D.E., Flu ge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in patients with COPD. Eur. Respir. J. 2004; 23: 832–840.

10. Qaseem A., Snow V., Shekelle P. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2007; 147: 633–638.

11. Mahler D., Donohue J., Barbee R. et al. Efficacy of Salmeterol Xinafoate in the Treatment of COPD. Chest 1999; 115: 957–965.

12. Dahl R., Greefhorst L., Nowak D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778.

13. Pauwels R.A., Buist A.S., Calverley P.M.A. et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1256–1276.

14. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 2002;113 (1): 59–65.

15. Sin D.D., Tu J.V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 580–584.

16. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society study on chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340: 1948–1953.

17. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819–1823.

18. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 1084–1091.

19. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902–1909.

20. Calverley P., Pauwels R., Vestbo J. et al, for the TRISTAN study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361: 449–456.

21. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.

22. Hanania N.A., Darken P., Horstman D. et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834–843.

23. Sin D.D., Anthonisen N.R., Soriano J.B. et al. Mortality in COPD: role of comorbidities. Eur. Respir. J. 2006; 28: 1245–1257.

24. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 1084–1091.

25. Gartlehner G., Hansen R.A., Carson S.S. et al. Efficacy and safety of inhaled corticosteroids in patients with copd: a systematic review and meta-analysis of health outcomes. Ann. Fam. Med. 2006; 4: 253–262.

26. Cazzola M., Dahl R. Therapy with long-acting β-agonists and 2 inhaled combination corticosteroids in stable COPD chest 2004; 126: 220–237.

27. Dal Negro R.W., Pomari C., Tognella S. et al. Salmeterol & fluticasone 50 g/250 g bid in combination provides a better long-term control than salmeterol 50 g bid alone and placebo in COPD patients already treated with theophylline. Pulm. Pharmacol. Ther. 2003; 16: 241–246.

28. Kardos P., Wencker M., Glaab T. et al. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructivepulmonary disease. Am. J. Respir. Crit. Care Med. 2007;175: 144–149.

29. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.

30. Calverley P., Anderson J., Bartolome C. et al. Salmeterol and Fluticason Propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.

31. Wedzicha J.A., Calverley P.M.A., Seemungal T.A. et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26.

32. Calverley P.M.A., Olsson H. Budesonide / formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD. Am. J. Respir. Crit. Care Med. 2003; 167: A319.

33. Jones P.W., Stahl E. Budesonide/formoterol in a single inhaler improves health status in patients with COPD. Am. J. Respir. Crit. Care Med. 2003; 167: A320.

34. Calverley P.M.A., Peterson S. Combining budesonide/ formoterol in a single inhaler reduces exacerbation frequency in COPD. Am. J. Respir. Crit. Care Med. 2003; 167: A948.

35. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, issue 4. Art. No.: CD006829. DOI: 10.1002/14651858.CD006829.

36. Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56: 880–887.

37. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebocontrolled trial. Lancet 2002; 360: 7–22.